Cancer Biomarkers Market in India

Cancer Biomarkers in India Trends and Forecast

The future of the cancer biomarkers market in India looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets. The global cancer biomarkers market is expected to reach an estimated $37.7 billion by 2031 with a CAGR of 14.5% from 2025 to 2031. The cancer biomarkers market in India is also forecasted to witness strong growth over the forecast period. The major drivers for this market are the increasing inclination towards personalized medicine for cancer treatment, the growing awareness of the importance of early detection of cancer, and the rising government support for cancer research.

• Lucintel forecasts that, within the cancer type category, breast cancer will remain the largest segment over the forecast period due to the increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.
• Within the application category, the diagnostic will remain the largest segment due to the increasing prevalence of cancer and the growing availability of cancer screening programs.

Emerging Trends in the Cancer Biomarkers Market in India

India’s cancer biomarkers market is witnessing rapid growth due to technological advances, rising awareness, and the demand for personalized medicine. Cancer biomarkers assist in early detection, diagnosis, and monitoring of treatment response and are becoming increasingly significant in oncology. The Indian healthcare sector is embracing advanced diagnostic technologies and treatments, facilitating improved patient outcomes. Some of the new trends building the market, fueled by innovation, regulatory requirements, and the demand for more effective cancer care solutions, include:

• Higher Adoption of Liquid Biopsy Technology: Liquid biopsy is revolutionizing cancer diagnostics with its non-invasive method of analyzing biomarkers found in blood samples to identify cancer. In India, this trend is growing because it offers early detection with less patient discomfort. Liquid biopsy also facilitates monitoring tumor growth and response to treatment, making it a valuable tool for personalized cancer therapy. With improvements in precision and feasibility, liquid biopsy has the potential to become a mainstream diagnostic modality in cancer care in India.
• Progress in Molecular Profiling: Molecular profiling involves examining genetic mutations and differences in cancer cells, enabling the use of targeted therapies. In India, developments in this field promise more personalized and efficient treatments for cancer patients. Personalized medicine is particularly driven by next-generation sequencing (NGS) technologies. By identifying specific genetic markers, clinicians can offer customized therapies, reducing the trial-and-error approach in treatment and maximizing therapeutic success rates.
• Increased Emphasis on Personalized Medicine: Personalized medicine, where treatment is tailored to the unique features of each patient, is on the rise in India. Cancer biomarkers play a central role in this approach by allowing the identification of specific genetic mutations and molecular signatures in patients’ cancers. By personalizing treatment based on these signatures, clinicians can improve therapy, reduce side effects, and enhance patient outcomes. As more cancer centers in India implement precision medicine practices, this trend will continue to grow, fostering a more efficient and patient-focused model of cancer care.
• Government Initiatives and Increased Funding: The Indian government is actively working to improve cancer diagnosis and treatment, creating favorable conditions for market growth. Initiatives like the National Cancer Grid and increased funding for cancer research have led to significant advances in cancer biomarker research and the commercial introduction of new diagnostic tests. These initiatives aim to make cancer care more accessible and affordable across the country, driving the growth of the cancer biomarkers market in India.
• Artificial Intelligence Integration in Cancer Diagnosis: Artificial intelligence (AI) is increasingly being incorporated into cancer diagnostic technologies, especially in biomarker analysis. AI can process vast amounts of data from liquid biopsies, imaging, and molecular profiles to assist physicians in making faster and more accurate decisions. In India, AI-driven tools are streamlining cancer diagnosis, enabling earlier detection, better prognosis, and improved treatment planning. As AI technology advances, its integration into the cancer biomarkers market will significantly transform the way cancers are diagnosed and treated in the country.

The Indian cancer biomarkers market is evolving rapidly, driven by trends such as the use of liquid biopsy technology, advances in molecular profiling, personalized medicine, government initiatives, and AI integration. These trends are helping to improve cancer detection, treatment, and patient outcomes, paving the way for a more sophisticated and patient-oriented approach to oncology in India.

Recent Developments in the Cancer Biomarkers Market in India

Current trends in India’s cancer biomarkers market represent a combination of technological innovations, regulatory changes, and the growing need for more accurate diagnostic technologies. The rapid adoption of advanced technologies like liquid biopsy, molecular profiling, and AI-based diagnostics is significantly transforming the oncology landscape. Moreover, government investments and private funding are further driving market growth. This transformation presents new challenges and opportunities for both patients and healthcare providers.

• Introduction of Liquid Biopsy for Early Detection: Liquid biopsy technology has transformed cancer diagnosis, enabling early detection of cancer from blood samples. The increased use of this non-invasive technique in India offers numerous benefits, such as reduced patient discomfort and faster results. In addition to early detection, liquid biopsy helps monitor the effectiveness of treatment and tumor growth. As more healthcare professionals adopt liquid biopsy, it is expected to become a routine diagnostic tool for several cancers, such as lung, breast, and colon cancer.
• Launch of Targeted Molecular Profiling Services: The introduction of advanced molecular profiling services in India allows clinicians to detect genetic mutations in patients’ cancers. By identifying specific genetic markers, clinicians can choose the best treatments, significantly enhancing patient outcomes. This development is at the core of the growth of precision medicine in India. Hospitals and diagnostic facilities are incorporating molecular profiling into their cancer treatment protocols, making personalized therapies more accessible to patients based on their unique genetic profiles.
• AI-Based Diagnostic Platforms for Cancer: AI-driven diagnostic platforms are being adopted in India’s cancer biomarkers industry, helping clinicians interpret complex data from imaging, molecular diagnostics, and biopsies. These platforms use machine learning algorithms to rapidly process large datasets and provide valuable insights for early diagnosis, prognosis prediction, and personalized treatment planning. AI is proving to be an essential tool in improving cancer diagnosis, and its future growth will further enhance healthcare services in India.
• Government Initiatives Supporting Biomarker Research: The Indian government has introduced several initiatives to fund cancer research, including biomarker-based tests. Through the National Cancer Grid and collaborations with global research institutions, India is focusing on improving cancer detection and treatment. These government-supported programs are increasing the availability and affordability of cancer biomarkers, allowing more individuals to benefit from early detection and targeted cancer therapies. As these programs gain momentum, they will drive further market expansion.
• Private Sector Investment Increase: Private sector investments in cancer research and biomarker-based diagnostics are steadily increasing in India. Startups and established companies are investing in developing innovative biomarkers and diagnostic devices to meet the growing demand for early detection and targeted treatment. These companies are advancing their research and expanding their market reach with venture capital funds. This influx of investment is accelerating the commercialization of cancer biomarkers and intensifying competition in the market.

Recent developments in India’s cancer biomarkers market have been transformative, from the widespread use of liquid biopsy and molecular profiling to government support and AI integration. These advancements are driving more precise, personalized, and effective cancer treatments, improving patient outcomes nationwide.

Strategic Growth Opportunities for Cancer Biomarkers Market in India

India’s cancer biomarkers market offers tremendous growth potential across various applications. As the country’s healthcare system continues to develop, there is increasing demand for innovative diagnostic solutions and personalized treatments. The strategic growth opportunities in the market include areas such as early cancer detection, precision medicine, and the implementation of AI technologies. By capitalizing on these opportunities, stakeholders can enhance patient care and further expand the market for cancer biomarkers in India.

• Early Cancer Detection Through Liquid Biopsy: The increasing use of liquid biopsy technology for early cancer detection presents a key growth opportunity. Liquid biopsies allow for more effective treatment measures by identifying cancer in its early stages. In India, this non-invasive procedure can significantly improve survival rates by detecting cancers before they reach advanced stages. As the technology becomes more accessible and affordable, liquid biopsy has the potential to dominate early cancer detection, particularly in rural areas.
• Growth of Personalized Medicine: Personalized medicine, which customizes treatment based on the genetic profile of patients, is a growing opportunity in India. With enhanced access to molecular profiling technologies, clinicians can identify specific biomarkers that predict treatment responses. This has made personalized oncology treatments more accessible in India, allowing patients to receive treatments with a higher likelihood of success. As more hospitals and diagnostic centers adopt personalized medicine, the market is expected to grow significantly.
• AI Integration to Amplify Diagnostics: The integration of AI in cancer diagnostics holds promising growth prospects. AI systems are designed to process complex data from various sources, such as genetic sequencing, imaging, and liquid biopsies, enabling clinicians to make more accurate diagnoses and treatment plans. In India, where healthcare resources are often limited, AI-driven diagnostic platforms can greatly enhance efficiency and patient outcomes. The development of AI in cancer diagnostics could revolutionize cancer detection and treatment in India, presenting a significant market growth opportunity.
• Government and Private Sector Collaboration: Collaboration between the Indian government and the private sector offers a unique opportunity for the cancer biomarkers market. With increased government investment in cancer research, combined with innovation from the private sector, the market is poised for significant growth. Public-private partnerships are encouraging the development of new biomarker-based treatments and diagnostic tests. These collaborations will also help improve access to quality cancer care, especially in underserved regions of the country.
• Emphasis on Oncology Biomarkers for Targeted Therapies: The growing focus on developing biomarkers that predict responses to targeted therapies is another major growth opportunity in India. Targeted therapies, which focus on specific molecular targets involved in cancer, are proving to be highly effective. As India’s healthcare infrastructure improves, the demand for these biomarker-driven therapies will increase, offering substantial market potential.

Strategic growth opportunities in India’s cancer biomarkers market are being driven by the demand for early cancer detection, personalized medicine, AI integration, and public-private collaborations. These opportunities will make cancer treatment in India more precise and efficient, resulting in improved patient outcomes and increased demand for cancer biomarkers.

Cancer Biomarkers Market in India Driver and Challenges

India’s cancer biomarkers market is influenced by a variety of drivers and challenges, including technological, economic, and regulatory factors. Advancements in cancer diagnostics and personalized medicine are driving market growth, while challenges related to infrastructure, awareness, and affordability must be addressed for these innovations to be widely adopted. Below are the key drivers and challenges affecting the market in India.

The factors responsible for driving the cancer biomarkers market in India include:
• Technological Advances in Diagnosis: The ongoing evolution of diagnostic technologies, particularly in molecular profiling, liquid biopsy, and AI, is a major growth driver for the cancer biomarkers market in India. These technologies enable early detection, precise diagnoses, and effective treatment protocols. As Indian healthcare providers increasingly adopt these technologies, the market for cancer biomarkers is expected to grow significantly, with improvements in diagnostic accuracy and personalized treatments.
• Government Initiatives and Support: The Indian government has been actively supporting cancer research and healthcare infrastructure development. Programs like the National Cancer Grid and funding for biomarker-based research are driving market growth. These government-backed initiatives have improved the accessibility and affordability of cancer care, especially in rural areas, and fostered innovation in cancer diagnostics. As these initiatives expand, they will continue to drive market growth.
• Growing Cancer Incidence: India is witnessing a rise in cancer cases due to demographic aging, lifestyle changes, and environmental factors. This growing cancer burden is a key driver of demand for advanced diagnostic technologies and therapies. The need for effective biomarkers for early diagnosis and personalized treatments will continue to grow, presenting significant opportunities for the cancer biomarkers market in India.
• Growing Patient Awareness: As awareness of cancer prevention and early detection increases, more patients are seeking advanced diagnostic services. This growing awareness is driving demand for cancer biomarkers, particularly in urban areas where access to modern healthcare facilities is better. As patients become more knowledgeable about their options, the demand for precise diagnostic tools, including biomarkers, will rise, fueling market growth.
• Private Sector Investment: Private sector investment in cancer research, biotechnology, and diagnostic technologies is accelerating the growth of the cancer biomarkers market in India. Venture capital and private equity funding are driving innovation, leading to the development and commercialization of new diagnostic tests and treatments. This influx of investment is expanding the market and creating opportunities for more advanced and affordable cancer care options.

Challenges in the cancer biomarkers market in India are:
• Insufficient Healthcare Infrastructure: One of the major challenges facing the cancer biomarkers market in India is the lack of sufficient healthcare infrastructure, particularly in rural areas. Many regions lack access to state-of-the-art diagnostic tools and treatment facilities, limiting the widespread adoption of advanced cancer biomarkers. Improving infrastructure is essential to ensure equitable access to cancer diagnostics and therapies across the country.
• High Cost of Cancer Care: The high cost of cancer care, including biomarker-based diagnostic tests and targeted therapies, is a significant barrier to adoption in India. Although government initiatives aim to improve affordability, the overall cost of cancer treatment remains prohibitive for many people. This economic challenge may limit access to life-saving biomarker-based diagnostics for a large portion of the population, particularly in lower-income segments.
• Regulatory Challenges: The regulatory environment for cancer biomarkers in India is still evolving, with challenges related to approvals, standardization, and quality control. Delays in regulatory approvals for new diagnostic tests and treatments can slow market growth and hinder patient access to the latest innovations. Addressing these regulatory challenges is essential to ensure that cancer biomarkers can reach the market in a timely manner.

India’s cancer biomarkers market is experiencing rapid growth due to technological advancements, government support, and rising patient awareness. However, challenges related to healthcare infrastructure, the cost of cancer care, and regulatory hurdles must be addressed to fully realize the market’s potential. By overcoming these obstacles, India’s cancer biomarkers market can provide more accurate and accessible cancer diagnostics and treatments for patients.

List of Cancer Biomarkers Market in India Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, cancer biomarkers companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer biomarkers companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5

Cancer Biomarkers Market in India by Segment

The study includes a forecast for the cancer biomarkers market in India by type, cancer type, profiling technology, and application.

Cancer Biomarkers Market in India by Type [Analysis by Value from 2019 to 2031]:

• Protein
• Genetic
• Others

Cancer Biomarkers Market in India by Cancer Type [Analysis by Value from 2019 to 2031]:

• Lung
• Breast
• Leukemia
• Melanoma
• Colorectal
• Prostate
• Thyroid
• Kidney
• Others

Cancer Biomarkers Market in India by Profiling Technology [Analysis by Value from 2019 to 2031]:

• Omics
• Imaging
• Immunoassay
• Bioinformatics
• Others

Cancer Biomarkers Market in India by Application [Analysis by Value from 2019 to 2031]:

• Diagnostics
• R&D
• Prognostics
• Risk Management
• Others

Features of the Cancer Biomarkers Market in India

Market Size Estimates: Cancer biomarkers in India market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Cancer biomarkers in India market size by type, cancer type, profiling technology, and application in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different type, cancer type, profiling technology, and application for the cancer biomarkers in India.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer biomarkers in India.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What are the major drivers influencing the growth of the cancer biomarkers market in India?
Answer: The major drivers for this market are the increasing inclination towards personalized medicine for cancer treatment, the growing awareness of the importance of early detection of cancer, and the rising government support for cancer research.
Q2. What are the major segments for cancer biomarkers market in India?
Answer: The future of the cancer biomarkers market in India looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets.
Q3. Which cancer biomarkers market segment in India will be the largest in future?
Answer: Lucintel forecasts that breast cancer will remain the largest segment over the forecast period due to increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 10 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the cancer biomarkers market in India by type (protein, genetic, and others), cancer type (lung, breast, leukemia, melanoma, colorectal, prostate, thyroid, kidney, and others), profiling technology (omics, imaging, immunoassay, bioinformatics, and others), and application (diagnostics, R&D, prognostics, risk management, and others)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Cancer Biomarkers Market in India, Cancer Biomarkers Market in India Size, Cancer Biomarkers Market in India Growth, Cancer Biomarkers Market in India Analysis, Cancer Biomarkers Market in India Report, Cancer Biomarkers Market in India Share, Cancer Biomarkers Market in India Trends, Cancer Biomarkers Market in India Forecast, Cancer Biomarkers Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.